Decreasing the transmission risk from a potentially infectious person in any given 74 75 environment . EMG SPI-M advises that to decrease the risk of transmission from an infectious person the following non pharmaceutical interventions (NPIs) should be 76 considered: 70 SAGE 87 minutes: Coronavirus (COVID-19) response, 22 April 2021 - GOV.UK (www.gov.uk) 71 EMG, SPI-M and SPI-B: Considerations in implementing long-term ‘baseline’ NPIs, 22 April 2021 - GOV.UK (www.gov.uk) 72 EMG, SPI-M and SPI-B: Considerations in implementing long-term ‘baseline’ NPIs, 22 April 2021 - GOV.UK (www.gov.uk) 73 EMG, SPI-M and SPI-B: Considerations in implementing long-term ‘baseline’ NPIs, 22 April 2021 - GOV.UK (www.gov.uk) 74 SAGE 87 minutes: Coronavirus (COVID-19) response, 22 April 2021 - GOV.UK (www.gov.uk) 75 EMG, SPI-M and SPI-B: Considerations in implementing long-term ‘baseline’ NPIs, 22 April 2021 - GOV.UK (www.gov.uk) 76 EMG, SPI-M and SPI-B: Considerations in implementing long-term ‘baseline’ NPIs, 22 April 2021 - GOV.UK (www.gov.uk) 19 • Physical distancing (to reduce risk from respiratory droplets and short- 77 78 79 range aerosols) • Ventilation (to reduce risk from long duration exposure and far-fields 80 81 82 aerosol transmission) • Face coverings (to reduce emission of virus and exposure to droplets 83 and larger aerosols) .